Loading...
•
Jun 30, 2024
EyePoint Pharmaceuticals Q2 2024 Earnings Report
Announced financial results for the second quarter ended June 30, 2024, and highlighted recent corporate developments.
Key Takeaways
EyePoint Pharmaceuticals reported total net revenue of $9.5 million for the second quarter ended June 30, 2024, compared to $9.1 million for the same period in 2023. The company's cash and investments totaled $280.2 million as of June 30, 2024.
Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU™ in wet AMD on track for first patient dosing in 2024.
Positive twelve-month data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD continue to demonstrate favorable safety and efficacy.
Phase 2 VERONA trial of DURAVYU in DME fully enrolled with topline data anticipated in Q1 2025.
Cash and investments totaled $280.2 million on June 30, 2024, providing cash runway through Phase 3 wet AMD topline data for DURAVYU in 2026.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Revenue by Segment
Revenue by Segment
Product sales, net Revenue
CapyFin.comLicense and royalties Revenue
CapyFin.com Forward Guidance
The company expects the cash, cash equivalents and investments on June 30, 2024, will enable them to fund operations through anticipated Phase 3 wet AMD topline data for DURAVYU in 2026.
Revenue & Expenses
Visualization of income flow from segment revenue to net income